Epirubicin for breast cancer during pregnancy: a case report.

Epirubicin for breast cancer during pregnancy: a case report. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Epirubicin for breast cancer during pregnancy: a case report. Abstract Text:

Padma Eedarapalli,Nibedan Biswas,Matthew Coleman,Padma Eedarapalli,Nibedan Biswas,Matthew Coleman,

BACKGROUND: The rarity of breast cancer in pregnancy and conflict between the optimal maternal therapy and fetal risks make its management challenging. Chemotherapy is the standard treatment for advanced cases. Epirubicin as a combination agent has been reported for breast and other cancers in pregnancy but not as a single agent. We report a case of advanced breast cancer treated with epirubicin neoadjuvant chemotherapy in pregnancy. CASE: A 30-year-old primigravida with multifocal, grade 3 invasive ductal carcinoma, stage T2 N1M0, received 4 cycles of primary epirubicin chemotherapy in pregnancy from 23 weeks' gestation. The chemotherapy was well tolerated by the mother and fetus, and a good response was achieved prior to postnatal combination chemotherapy and definitive surgery. CONCLUSION: Epirubicin chemotherapy appears safe and effective in pregnancy.

Epirubicin for breast cancer during pregnancy: a case report. Publishing Authors By Initials

P Eedarapalli,N Biswas,M Coleman,P Eedarapalli,N Biswas,M Coleman,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Epirubicin for breast cancer during pregnancy: a case report. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Journal of reproductive medicine

VOLUME: 52

Page Numbers: 730-2

Journal Abbreviation:

ISSN: 0024-7758

DAY: 20

MONTH: Aug

YEAR: 2007

Epirubicin for breast cancer during pregnancy: a case report. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 173343

Epirubicin for breast cancer during pregnancy: a case report. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Epirubicin for breast cancer during pregnancy: a case report. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Epirubicin for breast cancer during pregnancy: a case report.

AFFILIATION: Department of Obstetrics and Gynaecology, Poole Hospital, NHS Trust, Longfleet Road, Poole BH 15 2JB, UK. padmakumari2003@yahoo.co.uk

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Reprod Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Epirubicin for breast cancer during pregnancy: a case report Related Publications

• Ability to Exceed a Training Threshold During Tennis Activity in Persons with Physical Disabilities: 2279: Board #192 June 1 8:00 AM -9:30 AM.
• Accuracy, repeatability, and reproducibility of Artemis very high-frequency digital ultrasound arc-scan lateral dimension measurements.
• An increase in DNA double-strand breaks, induced by Ku70 depletion, is associated with human papillomavirus 16 episome loss and de novo viral integration events.
• Antigenicity of the Aeromonas salmonicida maltose-inducible outer membrane porin (maltoporin) and a hybrid protein derived from it.
• Clustering of hydatid infection in macropodids.
• Commentary: Is epidemiology really dead, anyway? A look back at Kenneth Rothman's 'The rise and fall of epidemiology, 1950-2000 AD'.
• DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
• Dissecting the molecular mechanisms of cancer through bioinformatics-based experimental approaches.
• Epirubicin for breast cancer during pregnancy: a case report.
• Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance.
• High-frequency ultrasonic imaging of the anterior segment using an annular array transducer.
• How do I fatten thee? Let me count the ways...
• Increased oxidative stress is associated with balanced increases in hepatocyte apoptosis and proliferation in glycerol-3-phosphate acyltransferase-1 deficient mice.
• Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
• Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.
• Modification of the aerobic cytotoxicity of etanidazole.
• Molecular cloning and nucleotide sequence analysis of the maltose-inducible porin gene of Aeromonas salmonicida.
• Mutagenesis of rat acyl-CoA synthetase 4 indicates amino acids that contribute to fatty acid binding.
• NAD(+) and axon degeneration revisited: Nmnat1 cannot substitute for Wld(S) to delay Wallerian degeneration.
• Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol 2007; 18 Suppl 3: pp 1 75).
• Overexpression of rat long chain acyl-coa synthetase 1 alters fatty acid metabolism in rat primary hepatocytes.
• Precocious development of hydatid cysts in a macropodid host.
• Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.
• Promoting bicycle helmet wearing by children using non-legislative interventions: systematic review and meta-analysis.
• Purification of immunoglobulins from chicken sera by thiophilic gel chromatography.
• Questioning specialists' attitudes to breast cancer follow-up in primary care.
• Recruitment and retention of children in longitudinal research.
• Regulation of Triglyceride Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action.
• Treatment with 2-AAF blocks the small hepatocyte-like progenitor cell response in retrorsine-exposed rats.
• Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.